860 results about "Blood lipids" patented technology

The invention relates to selenium-rich health-care rice dumplings. The selenium-rich health-care rice dumplings are prepared from the following raw materials of selenium-rich glutinous rice, rose petals, haw tree parasitism, plum tree parasitism, radix rehmanniae, dendrobium candidum, vegetable oil, pork, mung beans, ground cinnamon and table salt. The selenium-rich glutinous rice is used as a main raw material, so that selenium elements in human bodies are complemented, and collective antioxidation is strengthened; besides, the glutinous rice and the mung beans are soaked in a traditional Chinese medicine extracting solution, and medical components in traditional Chinese medicines are absorbed, so that the selenium-rich health-care rice dumplings have the efficacies of clearing heat, promoting salivation, relieving restlessness, resolving stagnation, reducing blood lipid, promoting digestion and enhancing the immunity of organisms.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The invention discloses a polypeptide or a pharmaceutically acceptable salt thereof. The polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or an amino acid sequence in a conservative modification form thereof. The polypeptide or the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP1R and is used for effectively activating the GLP1R. The GLP1R activating polypeptide is obtained through precise calculation and deep learning model optimization, has a short sequence, has unique amino acid arrangement compared with a traditional GLP-1 analogue, can effectively activate a GLP1R receptor, can also be used for treating or preventing metabolic disorder related diseases, and has a good application prospect. For example, obesity, diabetes, dyslipidemia related diseases, fatty liver diseases, metabolic syndromes, non-alcoholic fatty liver diseases and the like.

The invention relates to the field of medicines, foods or health-care products, in particular to big-fruit hawthorn heteropolysaccharide as well as a preparation method and application thereof. The large-fruit hawthorn heteropolysaccharide is prepared from galacturonic acid, glucuronic acid, mannose, xylose, arabinose, glucose, galactose, fucose and rhamnose. The weight-average molecular weight of the big fruit hawthorn heteropolysaccharide is 81.6 kDa to 157.3 kDa. The product has unique structures of complex monosaccharide composition, low molecular weight, appropriate uronic acid content, low esterification degree and the like; compared with CP which is single in structure and high in esterification, the CP is better in oxidation resistance and bile acid binding capacity; compared with hawthorn polysaccharide with low uronic acid content and high molecular weight, the hawthorn polysaccharide has the advantages that the enzyme inhibition activity is obviously enhanced, and the hawthorn polysaccharide has a wide prospect in development of functional food, health care products or medicines for regulating blood sugar / blood fat, resisting oxidation and preventing metabolic syndromes.

The invention provides application of a monascus composition in preparation of a medicine for preventing and / or treating coronary microcirculation disturbance. The monascus composition comprises one or more of cortex mori, ramulus mori and folium mori, monascus and radix puerariae. When the composition containing the red yeast rice is applied to preparation of the medicine for preventing and / or controlling coronary microcirculation disturbance, the abnormal microvascular structure can be improved (myocardial microvascular density MVD is increased, edema around microvessels is relieved, the lumen stenosis phenomenon is improved, and the endothelial cell condition is good); 2) microvascular occlusion is improved (pathologic results show that microvascular contents are reduced); (3) the abnormal vasodilatation and contraction function of the microvessels is improved (NO is increased); 4) improving blood lipid metabolism disorder; and (5) the heart function is improved (the left ventricular ejection fraction LVEF and the left ventricular short axis shortening rate LVFS are improved, and the left ventricular pressure maximum rising rate LV + dp / dtmax and the left ventricular pressure maximum falling rate LV-dp / dtmax are increased).

The invention belongs to the technical field of biological medicines, and particularly discloses a composition with functions of reducing blood sugar and blood fat as well as a preparation method and application of the composition. Chinese herbal compound medicinal materials are subjected to water extraction and high-temperature and high-pressure sterilization, and lactobacillus rhamnosus SHA113 bacterial sludge is resuspended in a water extract to obtain the composition of lactobacillus rhamnosus SHA113 and the Chinese herbal compound; the traditional Chinese medicine compound composition comprises astragalus membranaceus, raw Chinese yam, hawthorn, gynostemma pentaphylla, liquorice and jujube; the preservation number of the lactobacillus rhamnosus SHA113 is CCTCC (China Center For Type Culture Collection) NO: M 2017838; the lactobacillus rhamnosus SHA113 and traditional Chinese medicine compound composition can remarkably reduce the content of triglyceride and cholesterol in serum, control the fasting blood-glucose level, relieve accumulation of triglyceride and cholesterol in the liver and improve the oxidation resistance of the liver, has wide market potential and application prospects, and has wide application prospects. The compound can be applied to preparation of drugs for reducing blood sugar and blood fat.

The invention discloses a cape jasmine and fennel compound extract and a preparation method and application thereof, and belongs to the technical field of plant extracts.The preparation method of the cape jasmine and fennel compound extract comprises the steps that S1, a cape jasmine extract is prepared; s2, preparing a fennel extract; s3, the fennel extract and the fructus gardeniae extract are mixed according to a certain proportion to obtain the fructus gardeniae and fennel compound extract, the fennel extract prepared through the preparation method comprises an oil component and a water-soluble component, the compound extract achieves the effect of 1 + 1 > 2, has the remarkable effect of reducing blood fat and blood sugar, does not have side effects, and is suitable for large-scale popularization and application. The traditional Chinese medicine composition has an obvious regulating effect on blood pressure and blood fat of patients, has the efficacy of improving blood pressure, blood fat and blood sugar of patients, and is nontoxic and harmless to human bodies and free of side effects.

The invention belongs to the field of microorganisms, and provides lactobacillus paracasei Jlus660321 with a function of assisting in reducing blood fat and cholesterol and application of the lactobacillus paracasei Jlus660321, and the preservation number of the lactobacillus paracasei Jlus660321 is CGMCC No. 33962. The lactobacillus paracasei Jlus 660321 has the functions of assisting in lowering blood fat and lowering cholesterol, shows excellent cholesterol lowering performance in a cholesterol degradation experiment, and can degrade 61.60% of cholesterol in the experiment. A hemolysis experiment result is gamma-hemolysis, namely, hemolysis is avoided, and toxic and side effects are small. Rat in-vivo experiments show that the lactobacillus paracasei Jlus 660321 can effectively slow down the increase of body weight, liver weight, liver index, low-density lipoprotein content and triglyceride content caused by high-fat diet, and further show that the lactobacillus paracasei Jlus 660321 has the function of assisting in reducing blood fat and cholesterol; the compound can be used for preparing medicines, nourishment or health care products for assisting in reducing blood fat and / or reducing cholesterol.

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention discloses a composition for assisting in reducing blood sugar and blood fat as well as a preparation method and application thereof, and relates to the technical field of functional compositions. The composition comprises highland barley powder and modified inulin, the preparation method of the highland barley powder comprises the following steps: soaking highland barley grains in a weakly alkaline aqueous solution, and sequentially carrying out first pulse microwave treatment, enzyme deactivation treatment and segmented baking treatment; the segmented baking treatment comprises first-stage baking treatment and second-stage intermittent infrared irradiation treatment; the temperature of the first-stage baking treatment is 40-60 DEG C; the temperature of the second-stage intermittent infrared irradiation treatment is 60-80 DEG C, and the emission wavelength is 2.5-4 microns; the preparation method of the modified inulin comprises the following steps: performing acidolysis treatment on inulin in a weakly acidic aqueous solution, and then drying. The highland barley powder and the modified inulin in the embodiment can synergistically improve glycometabolism and lipid metabolism, effectively reduce the body weight, blood sugar, blood fat and the like under high-glucose and / or high-fat diet, and protect and repair the pancreas islet function.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus plantarum GL-2 and application thereof. The invention provides a strain of lactobacillus plantarum which is preserved in the 8th road of Wuchang District in Wuhan City, Hubei Province on March 15, 2023, and the preservation number is CCTCC M 2023328. The results of the embodiment show that the lactobacillus plantarum GL-2 provided by the invention has the effects of reducing blood sugar and blood fat, and the lactobacillus plantarum GL-2 provided by the invention also has the effects of repairing inflammation damaged organs and regulating intestinal microorganisms.

The invention discloses a compound bacterial agent for reducing blood sugar and blood fat, application of the compound bacterial agent and a method for preparing a fermented coconut milk beverage from the compound bacterial agent, belongs to the technical field of microorganisms, and particularly relates to the compound bacterial agent for reducing blood sugar and blood fat, the compound bacterial agent comprises fermented lactobacillus mucus AL-8 and lactobacillus paracasei DX-5, and the compound bacterial agent is prepared from the fermented lactobacillus mucus AL-8, the lactobacillus paracasei DX-5, the lactobacillus paracasei DX-5, the lactobacillus paracasei DX-5 and the lactobacillus paracasei DX-5 and the lactobacillus paracasei DX-5 and the lactobacillus paracasei DX-5 and the lactobacillus paracasei DX-5 and the lactobacillus paracasei DX-5. The preservation number of the lactobacillus mucus AL-8 is CCTCC (China Center For Type Culture Collection) NO: M20252735; the preservation number of the lactobacillus paracasei DX-5 is CCTCC (China Center For Type Culture Collection) NO: M20252736. According to the invention, the fermented coconut milk beverage is prepared by utilizing the inhibition effect of a blood sugar and blood fat reducing compound bacterial agent consisting of fermented lactobacillus mucus AL-8 and casei paracasei DX-5 on alpha-amylase and pancreatic lipase.

Incretin analogs are provided that have activity at each of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of health-care food, and particularly relates to a sacha inchi oil-based gel candy with functions of reducing hypertension, hyperglycemia and hyperlipidemia and a preparation method thereof, and the sacha inchi oil-based gel candy comprises the following components: 1) a main component: 30-70% of sacha inchi oil; 2) a blood fat reducing synergistic component which is one or a combination of more of 0.5%-5% of phytosterol, 0.1%-2% of a red yeast rice extract and 0.01%-0.5% of sugarcane octacosanol; 3) a hypoglycemic synergistic component, which comprises one or a combination of more of 5%-20% of inulin / fructo-oligosaccharide, 0.5%-5% of a bitter gourd extract, 0.5%-5% of a mulberry leaf extract and 10-200 [mu] g / grain of chromium; 4) an antihypertensive synergistic component, wherein the antihypertensive synergistic component is one or a combination of more of 500-5000FU / grain of nattokinase, 0.5-5% of a celery seed extract and 1-8% of a hawthorn extract; through scientific compounding, the sacha inchi oil and various synergistic components exert a combined effect, and meanwhile, auxiliary regulation is carried out on blood sugar, blood fat and blood pressure; the main components are derived from natural plant extracts or functional grease, so that the health-care product is high in safety and suitable for daily health care.

The invention belongs to the technical field of medicines, and particularly relates to a plant lactobacillus for relieving acute alcoholic liver injury as well as a metagen and application of the plant lactobacillus. The strain of the plant lactobacillus L5-13 is preserved in the China Center for Type Culture Collection on August 18, 2025, and the preservation number of the strain is CCTCC NO: M 20251835. The strain and the metagen thereof can significantly improve pathological symptoms of mice with acute alcoholic liver injury, including: reducing the levels of ALT, AST, TC, TG and LDL-C in serum of the mice with acute alcoholic liver injury, and increasing the level of HDL-C; the abnormal blood lipid level of the mouse caused by acute alcohol is regulated; the activity of antioxidant enzymes in the liver is improved, and the lipid peroxidation level is reduced; the ethanol dehydrogenase activity of the liver is improved, and the ethanol metabolism capability is enhanced. Therefore, the strain and the metagen thereof have wide application prospects in prevention or treatment of acute alcoholic liver injury.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The invention discloses a blood fat monitoring system based on a vascular ultrasound image, and belongs to the technical field of medical image recognition. The problems that an existing system cannot automatically recognize the blood vessel structure and evaluate the blood fat level and cannot ensure the stability and real-time performance of data transmission are solved, the intima-media membrane and lumen contours in the blood vessel ultrasonic image are automatically recognized in a short time through the convolutional neural network model, multi-dimensional features are extracted from the intima-media membrane and lumen contours, and the accuracy of the blood vessel ultrasonic image is improved. The identification precision and the diagnosis accuracy are improved; a multi-node gateway communication channel is arranged, and an optimal gateway is selected for data feedback in combination with a network distance threshold value, so that a blood fat prediction result is fed back to a medical interaction terminal in real time, it is ensured that early warning is triggered in time when the blood fat level exceeds a normal range, and the situation that a certain gateway breaks down or the communication distance exceeds the threshold value is prevented. And the system can be automatically switched to other available gateways, so that the stability and the reliability of the data in the transmission process are ensured.

The present application relates to use of Ligilactobacillus salivarius in preparing a drug for preventing and / or treating diseases associated with overweight and / or obesity . The strain can inhibit the weight growth of a high-fat diet-induced obesity model mouse, reduce the blood lipid level of the high-fat diet-induced obesity model mouse, improve the liver injury index of the high-fat diet-induced obesity model mouse, reduce the area of white adipose cells of the high-fat diet-induced obesity model mouse, improve the colon GLP-1 level of the high-fat diet-induced obesity model mouse, improve the intestinal flora imbalance of the high-fat diet-induced obesity model mouse, and improve the liver glycolipid metabolism of the high-fat diet-induced obesity model mouse; and reduce the waist circumference, hip circumference, body fat mass, BMI, and weight of overweight and overweight and / or obesity volunteers, and maintain the muscle content, promoting overweight and overweight and / or obesity people to carry out safe, effective, and sustainable weight management.

The present invention belongs to the technical field of plant extracts, and more specifically, relates to the use of a carob extract in a drug for improving glucose metabolism / polycystic ovary syndrome in women. The present invention discloses a pharmaceutical composition for improving glucose metabolism and treating polycystic ovary syndrome in women, the pharmaceutical composition comprising: carob extract, baicalein, cedrol, a bioactive peptide, a biopolysaccharide, and excipients. The composition of the present invention has the effects of lowering blood sugar and blood lipids, improving insulin function, and also has antioxidant and immunity-enhancing effects. By combining the above substances, a synergistic effect is achieved, further enhancing the effect of improving / treating polycystic ovary syndrome in women associated with abnormal glucose metabolism.

The invention discloses giant salamander grease and application thereof in a blood fat reducing product. The giant salamander grease is obtained by adding papain into giant salamander tissues for enzymolysis and then adsorbing by using an egg white modified microsphere adsorbent. The giant salamander grease is refined by using the egg white modified microsphere adsorbent, and then the giant salamander grease is compounded with the dark tea extract, the hawthorn extract and the lotus leaf extract and processed into embedded particles, so that the water solubility of the giant salamander grease preparation can be improved, and the giant salamander grease preparation can be used as an oral preparation for reducing blood fat.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The invention discloses a traditional Chinese medicine composition for preventing and treating metabolism-related fatty liver diseases or metabolic syndromes. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-50 parts of sweet wormwood, 3-30 parts of scutellaria baicalensis, 5-50 parts of dandelion, 4-60 parts of platycodon grandiflorum, 5-50 parts of fructus aurantii, 3-80 parts of rhizoma pinelliae preparata, 3-70 parts of fructus amomi, 10-80 parts of stir-fried Chinese yam, 5-80 parts of poria cocos and 3-100 parts of raw coix seeds. The traditional Chinese medicine composition for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes is simple in formula, proper in compatibility and mild in medicine property, is used for preventing and treating the metabolism-related fatty liver diseases or the metabolic syndromes, is used for improving liver fatty degeneration and inflammation, blood uric acid, blood fat, blood sugar and blood pressure, assisting weight loss and the like, and is safe to use and remarkable in curative effect.

The invention relates to the technical field of functional probiotic screening and application, and particularly provides a bifidobacterium animalis subsp. Lactis (Bifidobacterium animalis subsp. Lactis) capable of relieving liver injury and regulating glycolipid metabolism and application of the bifidobacterium animalis subsp. Lactis. The preservation number of the bifidobacterium animalis subsp. Lactis is CGMCC No.31656, and the bifidobacterium animalis subsp. Lactis can effectively reduce blood sugar and blood fat of diabetic mice and relieve insulin resistance and has the capacity of relieving diabetic cardiomyopathy. The strain has wide application prospects in preparation of drugs for treating diabetes mellitus, liver injury and glycolipid metabolism.

The invention relates to the technical field of glucometers, and discloses an intelligent multifunctional glucometer supporting data cloud storage and remote analysis, which comprises hardware, detection, data processing, wireless communication, a cloud server platform and an interactive terminal module to form a complete data closed loop. The hardware module is composed of an upper shell and a lower shell which are clamped, and the upper shell is provided with a detection port, an operation button and anti-skid lines. The detection module is integrated with an electrochemical sensor array and can synchronously detect blood glucose, uric acid, ketone body and blood fat. The data processing unit processes data in real time to generate a health report, and the wireless communication module supports multi-mode communication and encrypted transmission. The cloud platform stores data and outputs suggestions through machine learning, and the interactive terminal supports biological recognition and voice broadcast. The modules cooperate to realize multi-index detection, cloud analysis and intelligent interaction. The system has the advantages of multi-index synchronous detection, data security intelligent analysis and convenient interaction, and supports data cloud storage and remote analysis.

The present invention relates to Akkermansia muciniphila Akk11 having the functions of regulating blood glucose and blood fat and the use thereof. Said Akkermansia muciniphila Akk11 is classified and named as Akkermansia muciniphila Akk11 with the accession number of CCTCC NO: M2024119. The strain uses mucin as the unique source of carbon element and nitrogen element, so as to control the basic regulatory systems of glucose and energy metabolism, protect the integrity of intestinal epithelial cells and mucus layers to exert a protective effect on metabolism, regulate the levels of blood glucose and blood fat, and remarkably relieve symptoms of metabolic disorders, and thus providing strategies and reference basis for the prevention and treatment of obesity.

A dual function protein is disclosed. The dual function protein may be prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. The dual function protein has improved pharmacological efficacy, in vivo duration and protein stability. The dual function protein exhibits improved pharmacological efficacy, in vivo duration and protein stability. A pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.